MarketCap
Regeneron Pharmaceuticals REGN
$ 827.72
3.42%
Facebook
X
Telegram
Regeneron Pharmaceuticals Operating Income | REGN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Regeneron Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.58 B | 3.99 B | 4.05 B | 4.74 B | 8.95 B | 3.58 B | 2.21 B | 2.53 B | 2.08 B | 1.33 B | 1.25 B | 824 M | 743 M | 458 M | -205 M | -97.5 M | -74.1 M | -86.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.95 B | -205 M | 2.21 B |
Quarterly Operating Income Regeneron Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 643 M | 1.03 B | 1.08 B | 592 M | 1.18 B | 1.07 B | 751 M | 1.11 B | 1.02 B | 947 M | - | 1.22 B | 1.11 B | 1.26 B | - | 1.85 B | 3.35 B | 1.11 B | - | 1.05 B | 656 M | 700 M | - | 738 M | 316 M | 480 M | - | 627 M | 622 M | 567 M | - | 560 M | 550 M | 431 M | - | 363 M | 292 M | 329 M | - | 392 M | 345 M | 284 M | 216 M | 824 M | 216 M | 216 M | - | 237 M | 158 M | 153 M | - | 202 M | 87.5 M | 22.2 M | - | -58.5 M | -60.3 M | -41 M | -32.1 M | -23.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 B | -60.3 M | 641 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-14.7 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
-24.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
-1.99 M | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Qilian International Holding Group Limited
QLI
|
-12.6 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
-14.7 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-14.3 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
178 M | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Abcam plc
ABCM
|
-10.1 M | - | - | $ 4.9 B |  Britain |
|
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-122 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-252 M | - | 2.43 % | $ 254 M | Germany |
 |
Codexis
CDXS
|
-41.7 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
-41 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Affimed N.V.
AFMD
|
-107 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
-12.1 M | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-105 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.43 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-625 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
-153 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
47.9 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-84 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-247 M | $ 4.3 | 1.42 % | $ 298 M | Britain |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.3 M | - | -0.88 % | $ 598 M | USA |